Janet Dubois

Nov 20, 2023 | onlinelibrary.wiley.com | Robert Bissonnette |Janet Dubois |Paola Facheris |Ester Del Duca

CCL17 C-C motif chemokine ligand 17 CCL22 C-C motif chemokine ligand 22 CCR4 C-C motif chemokine receptor 4 EASI Eczema Area and Severity Index EOT end of treatment MAD multiple ascending dose MADAD meta-analysis derived atopic dermatitis NL non-lesional SAD single ascending dose SCORAD SCORing Atopic Dermatitis Th T-helper cell 1 INTRODUCTION Atopic dermatitis (AD) is a chronic inflammatory skin disease that is estimated to affect ~15%–20% of children and up to 10% of adults worldwide, with...

May 3, 2023 | jamanetwork.com | Matthew Zirwas |Zoe D. Draelos |Janet Dubois |Leon Kircik

Key PointsQuestion  What is the efficacy and safety of once-daily roflumilast foam, 0.3%, in adult patients with seborrheic dermatitis? Findings  In this randomized clinical trial that included 226 patients with seborrheic dermatitis, 73.8% of roflumilast-treated patients achieved Investigator Global Assessment success at week 8 compared with 40.9% in the vehicle group, a statistically significant difference.